Table 1.

The calorie intake, body weight, and the Arc mRNA expressions after 4‐wk treatment and the c‐fos expression in the brain area of Arc, DMH, and LHA after 60‐min treatment

	Control	Risperidone	Risperidone + Lorcaserin	Lorcaserin
Body weight (g)	19.6 ± 0.231*	20.6 ± 0.216	19.6 ± 0.265**	18.5 ± 0.173***
Calorie intake (kcal)	8.6 ± 0.363*	10 ± 0.209	8.7 ± 0.183**	7.7 ± 0.107***
c‐Fos in the Arc	43.6 ± 3.572#	73.6 ± 4.02	/	/
c‐Fos in the DMH	42 ± 2.775#	115 ± 6.066	/	/
c‐Fos in the LHA	35 ± 4.946#	70.8 ± 5.389	/	/
mRNA in the Arc	22.4 ± 1.749*	32.2 ± 2.634	22.6 ± 1.536**	13.4 ± 0.927***

Data are means ± SEM, n = 4‐6 for each group. The differences were determined by either one‐way ANOVA with Tukey post hoc test for body weight and calorie intake or unpair t test for c‐fos analysis.

^* P < .05 vs risperidone or lorcaserin.

^** P < .05 vs risperidone or lorcaserin.

^*** P < .05 vs risperidone.

^# P < .05 vs risperidone.